SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: betty moyers who wrote (11112)7/10/1998 6:09:00 PM
From: VLAD  Read Replies (1) of 23519
 
betty,

the milestone payment will either be 2 million or 10 million.

So if all 4 of the European countries mentioned get approved in Q3 then it should be 12 million.

Assuming it is only 2 million then I get -2.2 million. I don't know what start up costs were for the factory in Q2 but you can add that to the -2.2 million......my guess would be that it is at least 2.2 million.

So based on those assumptions we have break even.

Now add about 32 cents if Europe gets approval PLUS income from product sales. It looks to me more like about a 10 to 20 cent quarter based on product sales. I think that if product sales are good and we get European approval it will be a blow out quarter.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News